Navigation Links
Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment
Date:11/14/2013

independent TP53 driver mutations, each of which was present in only subsets of the ovarian tumor samples. This level of heterogeneity was also manifested in different evolutionary pathways that each instance of cancer took, with some cancers following a linear progression while the TP53 instance displayed early branching, in which each branch has its own genetic set of mutations.

"Ovarian cancers are typically diagnosed when the disease is at an advanced stage and the tumor mass is often large with numerous metastases throughout the abdominal cavity," said Wigard P. Kloosterman, a principal investigator at the University Medical Center Utrecht and lead author of the study. "Following primary debulking surgery, we obtained a large number of samples from each of these women, which enabled the study of intra-tumor heterogeneity before chemotherapeutic or other drug treatments were applied. The current study, representing the most comprehensive data set to date, reveals extensive heterogeneity, which is probably one of the reasons this disease is so difficult to treat."

The study did reveal marked gene expression differences between tumor biopsies from the same patient. These include altered expression of WNT, integrin and Hedgehog pathway members in subsets of tumor biopsies. Currently, targeted therapies for ovarian cancer patients are being developed and proper patient stratification is essential for successful treatment. For example, application of Hedgehog pathway inhibitors is an emerging strategy that could only prove useful in those patients displaying changes in Hedgehog signaling. The results from this study suggest that fine-tuning of patient stratification for targeted therapy would require analysis of multiple biopsies per patient.

"This study is a key first step in the community's effort towards personalized medicine, one in which we characterize the mutational landscape within an individual's cancer," said Timothy Harkins, a Dir
'/>"/>

Contact: Suzanne Clancy
Suzanne.Clancy@lifetech.com
760-602-4545
Life Technologies
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Elseviers Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical
2. Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
3. Development and clinical approval of biodegradeble magnesium alloy
4. Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing
5. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
6. Breastfeeding as a possible deterrent to autism -- a clinical perspective
7. Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines
8. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
9. Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support
10. UNLV, Sen. Reid Announce $20 Million NIH grant to support clinical health research
11. Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... URBANA A new strategy to manage invasive species ... the Grand River Grasslands, an area within the North ... along with his colleagues at Iowa State and Oklahoma ... effort to establish a more diverse landscape for native ...
... 9, 2012More than half (52%) of the companies comprising ... revenue-generating, compared to about 21% four years ago, reports ... those companies, 31% have commercial products and 21% are ... to the current issue of GEN . ...
... July 11, and join a public forum with North ... Environmental Protection Agency Administrator Lisa P. Jackson, Canadian Environment ... Quesada. The webcast will kick off at 9 ... July 9 and 10 Joint Public Advisory Committee workshop ...
Cached Biology News:Grassroots approach to conservation developed 2Grassroots approach to conservation developed 3GEN reports on growth of tissue engineering revenues 2
(Date:7/31/2015)... HONG KONG , July 31, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... with the U.S. Securities and Exchange Commission. The filed ... year ended March 31, 2015. The Form 20-F can ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... on new patient data supporting the Ross heart, reconstruction procedure ... ... procedure, ATLANTA, Oct. 7 CryoLife, Inc. (NYSE: CRY ... surgeons from around the globe will participate in the,Ross Summit 2008, ...
... AMERIGROUP,Corporation (NYSE: AGP ) today announced ... quarter ended September 30, 2008, after the market ... Eastern Time on Thursday, October,23, 2008, AMERIGROUP,s management ... earnings and other information., To listen to ...
... to Save Millions of Lives, GERMANTOWN, Md., ... company focused on development of medical,countermeasures for biodefense ... a multiyear contract for advanced development of a,vaccine ... the National,Institute of Allergy and Infectious Diseases (NIAID), ...
Cached Biology Technology:CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 3
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... ZMD.414. Immunogen: Synthetic peptide derived from ... rat mTOR (Mammalian target of rapamycin FRAP ... human mTOR protein. On Western blots ... kDa. Reactivity: Human (positive control: HEK293 ...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
...
Biology Products: